Basic research of annexin V as a molecular target therapy for gynecologic cancer
膜联蛋白V作为妇科肿瘤分子靶向治疗的基础研究
基本信息
- 批准号:14571536
- 负责人:
- 金额:$ 2.24万
- 依托单位:
- 依托单位国家:日本
- 项目类别:Grant-in-Aid for Scientific Research (C)
- 财政年份:2002
- 资助国家:日本
- 起止时间:2002 至 2003
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Recently, molecular mechanism of proliferation and progression of carcinoma cells (infiltration and invasion) has been well understood. As a result, molecular target therapy of cancer patient is developing in Europe and the United States. Clinical trials of some tyrosine kinase inhibitors have already carried out as anti -cancer drugs. Although protein kinase C (PKC) representing Ser/Thr protein kinases is one of the most important kinases, no endogenous inhibitor in the cell has not been discovered. We first separated and purified annexin V from human placenta, which was a Ca^<2+>-dependent phospholipid binding protein, and reported to inhibite protein kinase C activity in vitro. The purpose of this study is to elucidate the role of annexin V in the cell and to clarify whether annexin V can inhibit tumor progression in the cell, followed by developing molecular target therapy of cancer patients with Ser/Thr protein kinase inhibitors by inhibiting tumor progression.We constructed annex … More in V-stably expressing human leukemia cell lines (HL-60). Although annexin V overexpression did not induce morphological changes in the cell lines, TPA-induced PKC activation was inhibited in annexin V overexpressing cells. We showed that PKCδ was a most likely, candidate of TPA targeting PKC isoforms that was inhibited by annexin V. Since annexin V overexpress ion did not induce phenotype, we approached biological function of annexin V by the elucidation of annexin V gene regulation. Our results suggest that (i)protein synthesis inhibitors (CHX, ANI) superinduce annexin V mRNA expression. (ii)TPA enhances CHX-induced the superinduction of annexin V mRNA in MCAS cells by activating PKC and mRNA transcription. (iii)ANI superinduces annexin V mRNA expression through the ERK1/2 MAPK pathway, but not through the p38 MAPK pathway. Taken together, these results indicated that the regulation of annexin V gene expression was negatively controlled at the transcription factor level, and that PKC and ERK1/2 pathway was involved in the induction of annexin V gene expression. Less
近年来,肿瘤细胞增殖和发展的分子机制(浸润性和侵袭性)已被人们所熟知。因此,肿瘤患者的分子靶向治疗正在欧美国家蓬勃发展。一些酪氨酸激酶抑制剂已经作为抗癌药物进行了临床试验。代表丝氨酸/苏氨酸蛋白激酶的蛋白激酶C(PKC)是最重要的蛋白激酶之一,但尚未发现细胞内的内源性抑制物。我们首次从人胎盘中分离和纯化了膜联蛋白V,它是一种依赖于钙离子的磷脂结合蛋白,据报道在体外可以抑制蛋白激酶C的活性。本研究的目的是阐明Annexin V在细胞中的作用,并阐明Annexin V是否能抑制细胞内的肿瘤进展,进而开发应用丝氨酸/苏氨酸蛋白激酶抑制剂抑制肿瘤进展的分子靶向治疗癌症患者。我们构建了附件…在V-稳定表达的人白血病细胞系(HL-60)中更多。虽然Annexin V过表达不会引起细胞形态的改变,但在Annexin V过表达的细胞中,TPA诱导的PKC活化被抑制。我们发现PKCδ是最有可能的针对膜联蛋白V抑制的蛋白激酶C亚型的候选蛋白,由于膜联蛋白V的过度表达不能诱导表型,因此我们通过阐明膜联蛋白V基因的调控来探讨膜联蛋白V的生物学功能。我们的结果提示:(1)蛋白质合成抑制剂(CHX、ANI)可明显诱导Annexin V基因的表达。(2)TPA通过激活PKC和mRNA转录,增强CHX诱导的MCAS细胞Annexin V mRNA的超诱导。(3)ANI通过ERK1/2 MAPK途径,而不是通过p38 MAPK途径,上调Annexin V mRNA的表达。综上所述,这些结果表明Annexin V基因表达的调控在转录因子水平上是负调控的,PKC和ERK1/2通路参与了Annexin V基因表达的诱导。较少
项目成果
期刊论文数量(18)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Yoshitomo Konishi: "12-O-tetradecanoylphorbol-13-acetate enhances superinduction of annexin V mRNA express on by cycloheximide in MCAS cells"Biochem Biophys Res Commun.. (in press). (2004)
Yoshitomo Konishi:“12-O-十四烷酰佛波醇-13-乙酸酯增强放线菌酮在 MCAS 细胞中对膜联蛋白 V mRNA 表达的超诱导”Biochem Biophys Res Commun..(出版中)。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Yoshitomo Konishi: "Anisomycin superinduces annexin V mRNA expression through the ERK1/2 but not th p38 MAP kinase pathway"Biochem Biophys Res Commun.. 313. 977-983 (2004)
Yoshitomo Konishi:“茴香霉素通过 ERK1/2 但不是 p38 MAP 激酶途径超级诱导膜联蛋白 V mRNA 表达”Biochem Biophys Res Commun.. 313. 977-983 (2004)
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Hirokazu Sato: "12-O-tetradecanoylphorbol-13-acetate induces annexin V expression through the extracellular signal-regulated kinase (ERK) signaling pathway in HL-60 cells"Oncogene. (in press). (2004)
Hirokazu Sato:“12-O-tetradecanoylphorbol-13-acetate 通过细胞外信号调节激酶 (ERK) 信号通路在 HL-60 细胞中诱导膜联蛋白 V 表达”Oncogene。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Yoshitomo Konishi: "Anisomycin superinduces annexin V mRNA expression through the ERK1/2 but not the p38 MAP kinase pathway."Biochem Biophys Res Commun.. 313. 977-983 (2004)
Yoshitomo Konishi:“茴香霉素通过 ERK1/2 但不是 p38 MAP 激酶途径超级诱导膜联蛋白 V mRNA 表达。”Biochem Biophys Res Commun.. 313. 977-983 (2004)
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Yoshitomo Konishi: "12-O-tetradecanoylphorbol-13-acetate enhances superinduction of annexin V mRNA expression by cycloheximide in MCAS cells"Biochem Biophys Res Commun.. (in press). (2004)
Yoshitomo Konishi:“12-O-十四烷酰佛波醇-13-乙酸酯通过放线菌酮在 MCAS 细胞中增强膜联蛋白 V mRNA 表达的超诱导”Biochem Biophys Res Commun..(出版中)。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SATO Hirokazu其他文献
SATO Hirokazu的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('SATO Hirokazu', 18)}}的其他基金
Contrastive research of accent and tone languages based on dynamics of suprasegmentals
基于超音段动力学的重音语言对比研究
- 批准号:
26284057 - 财政年份:2014
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Promotion of Early Inundated Water Drainage Using Artificial Levee Break
利用人工决堤促进早期淹没排水
- 批准号:
24710207 - 财政年份:2012
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Comparative study on suprasegmental characteristics among East and Southeast Asian languages
东亚和东南亚语言超音段特征比较研究
- 批准号:
23300093 - 财政年份:2011
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Application of annexin V to measurement of platelete activation
膜联蛋白V在血小板活化测定中的应用
- 批准号:
18591793 - 财政年份:2006
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
An analysis of the system of "Bibliotheque de Travil" in Pedagogie Freinet
弗雷内教育学中“旅行图书馆”体系分析
- 批准号:
02610115 - 财政年份:1990
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for General Scientific Research (C)
相似海外基金
Aberrant Protein Kinase C Signaling in Alzheimer's Disease
阿尔茨海默病中的异常蛋白激酶 C 信号转导
- 批准号:
10901015 - 财政年份:2023
- 资助金额:
$ 2.24万 - 项目类别:
Regulation of Protein Kinase C Theta by Phosphorylation
通过磷酸化调节蛋白激酶 C Theta
- 批准号:
10679152 - 财政年份:2023
- 资助金额:
$ 2.24万 - 项目类别:
RUI: Protein-Protein Interactions of Protein Kinase C During Polarized Growth in Filamentous Fungi
RUI:丝状真菌极化生长过程中蛋白激酶 C 的蛋白质-蛋白质相互作用
- 批准号:
2222841 - 财政年份:2023
- 资助金额:
$ 2.24万 - 项目类别:
Continuing Grant
Protein kinase C signaling in prostate cancer health disparities
前列腺癌健康差异中的蛋白激酶 C 信号传导
- 批准号:
10744533 - 财政年份:2023
- 资助金额:
$ 2.24万 - 项目类别:
Effectors of protein kinase C-mediated tumor progression
蛋白激酶 C 介导的肿瘤进展的效应器
- 批准号:
10543367 - 财政年份:2022
- 资助金额:
$ 2.24万 - 项目类别:
Regulation of placental epithelial cell death by atypical protein kinase-c
非典型蛋白激酶-c对胎盘上皮细胞死亡的调节
- 批准号:
573074-2022 - 财政年份:2022
- 资助金额:
$ 2.24万 - 项目类别:
University Undergraduate Student Research Awards
Structural optimization of vibsanins with scaffold diversity as protein kinase C activator
具有支架多样性的 vibsanins 作为蛋白激酶 C 激活剂的结构优化
- 批准号:
22K05464 - 财政年份:2022
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Regulation of trophoblast stem cell homeostasis and differentiation by atypical protein kinase-C isoforms
非典型蛋白激酶-C 亚型对滋养层干细胞稳态和分化的调节
- 批准号:
RGPIN-2021-02807 - 财政年份:2022
- 资助金额:
$ 2.24万 - 项目类别:
Discovery Grants Program - Individual
Regulation of trophoblast stem cell homeostasis and differentiation by atypical protein kinase-C isoforms
非典型蛋白激酶-C 亚型对滋养层干细胞稳态和分化的调节
- 批准号:
RGPIN-2021-02807 - 财政年份:2021
- 资助金额:
$ 2.24万 - 项目类别:
Discovery Grants Program - Individual